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Background: The characterization of HIV-1 transmission strains may inform the design of an effective vaccine.
Shorter variable loops with fewer predicted glycosites have been suggested as signatures enriched in envelope
sequences derived during acute HIV-1 infection. Specifically, a transmission-linked lack of glycosites within the V1
and V2 loops of gp120 provides greater access to an α4β7 binding motif, which promotes the establishment of
infection. Also, a histidine at position 12 in the leader sequence of Env has been described as a transmission
signature that is selected against during chronic infection. The purpose of this study is to measure the association
of the presence of an α4β7 binding motif, the number of N-linked glycosites, the length of the variable loops, and
the prevalence of histidine at position 12 with HIV-1 transmission. A case–control study design was used to
measure the prevalence of these variables between subtype B and C transmission sequences and frequency-
matched randomly-selected sequences derived from chronically infected controls.
Results: Subtype B transmission strains had shorter V3 regions than chronic strains (p= 0.031); subtype C
transmission strains had shorter V1 loops than chronic strains (p= 0.047); subtype B transmission strains had more
V3 loop glycosites (p= 0.024) than chronic strains. Further investigation showed that these statistically significant
results were unlikely to be biologically meaningful. Also, there was no difference observed in the prevalence of a
histidine at position 12 among transmission strains and controls of either subtype.
Conclusions: Although a genetic bottleneck is observed after HIV-1 transmission, our results indicate that summary
characteristics of Env hypothesised to be important in transmission are not divergent between transmission and
chronic strains of either subtype. The success of a transmission strain to initiate infection may be a random event
from the divergent pool of donor viral sequences. The characteristics explored through this study are important,
but may not function as genotypic signatures of transmission as previously described.
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Chronic infectionBackground
Multiple research groups have invested substantial effort
into defining signatures within the envelope protein
(Env) of HIV-1 that are highly predictive of viral trans-
mission [1-13]. A genetic bottleneck occurs at HIV-1
transmission, and early replicating viral populations re-
main homogenous [3], so that investigating the transmit-
ted strains across many individuals may reveal a* Correspondence: dfjp@unimelb.edu.au; jamesm@unimelb.edu.au
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reproduction in any medium, provided the ortransmission signature and point to a process important
in establishing infection [1,2,4-7]. These studies not only
provide insight into the biological processes occurring
during mucosal transmission, they may also inform the
development of an effective vaccine against HIV-1. The
discovery of a transmission signature could reveal motifs
that may be successfully targeted during vaccination
which could lead to a more protective response com-
pared to vaccines developed from chronically replicating
viral sequences [14-17].
A number of different approaches have been used to
identify transmission signatures, investigating whethertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cosylation sites (glycosites) are characteristics enriched
in Env from viruses derived during acute infection.
Comparing sequences from chronically infected donors
and early sequences of infected recipients is a more
powerful way to study transmission, although sample
sizes often remain small. Using eight donor-recipient
pairs, Derdeyn et al. showed significant differences in
subtype C Env sequences, where early V1-V4 loops were
shorter (p= 0.02) and had fewer glycosites (p= 0.037) [4].
Also using donor-recipient pairs, Frost et al. found no
difference between envelope length or the number of
glycosites in sequences derived from eight men who
have sex with men during acute infection and their
transmission pairs [18]. However, in the study Frost
et al. state that only half of the donors had confirmed
chronic infection, and that four were recently infected
donor subjects [18], which could bias the results. In ten
self-reported transmission pairs of subtype B, Liu et al.
showed that gp120 sequences had shorter variable
regions and reduced numbers of glycosites following
transmission to the new host [19]. However, they state
that their results were dependent upon how pairs were
chosen for inclusion, and that no other study had yet
found these reductions to be measured consistently
across various acute infections. Chohan et al. compared
35 early and 51 late sequences of subtype A and 13 early
and 82 chronic sequences of subtype B (chronic
sequences were selected from the Los Alamos HIV Se-
quence Database (LANL) [20]). They showed early
sequences had shorter loops (p= 0.008) and fewer glyco-
sites (p= 0.017) for subtype A, but not subtype B
(p= 0.340; p= 0.640, respectively) [5].
Other studies have suggested transmission-linked gly-
cosites in the V1 and V2 loops surrounding the α4β7
binding site are significant in terms of transmission
[11,15,21,22]. The V2 loop of gp120 contains an α4β7
binding site, defined as LDV/I at position 180 (according
to the HXB2 reference sequence) [11,21-23]. α4β7 is a
gut homing receptor colocalized with CCR5 and CD4 on
CD4+ T cells, and projects out further from the cell sur-
face than CCR5 or CD4 [11,21-24]. α4β7 +/CD4+ T cells
infected with HIV-1 will migrate to the gut, where HIV-
1 preferentially replicates and causes irrevocable damage
to the immune system [11,21-24]. Although not neces-
sary for HIV-1 entry into CD4+ T cells, Env lacking spe-
cific glycosites within the V1 and V2 loops of gp120
have greater access to bind α4β7, an interaction that has
been shown to promote a greater susceptibility to infec-
tion [11,15,22]. This increased capacity for infection may
be an important transmission signature [11,15]. How-
ever, no statistical analyses have been used to measure
the association of the absence of glycans in close prox-
imity to the α4β7 binding site and transmission.Recently, models scanning the entire Env sequence for
patterns in amino acids have been used to search for
transmission signatures in subtype B Env sequences
[1,2]. Gnanakaran et al., through a retrospective
hypothesis-raising ‘test’ analysis, found that a histidine
(His) at position 12 in the Env leader sequence was asso-
ciated with transmission because it was selected against
in chronic infection [1,2]. Asmal et al. supported this
phenotypically, showing that Env sequences containing a
positively charged amino acid at position 12 were asso-
ciated with higher levels of expression due to more effi-
cient trafficking of the nascent polypeptide to the
endoplasmic reticulum [2].
Here, we applied an epidemiological approach to in-
vestigating the transmission signature, using a case–con-
trol study design to measure associations between HIV-1
transmission strains (‘cases’) and chronic infection
strains (‘controls’). Case–control studies are often used
in epidemiology and measure exposure variables be-
tween cases with the outcome of interest, in this study, a
transmission event, and randomly selected population
controls [25,26]. The transmission strains used in this
study were consensus sequences (obtained through
backwards phylogeny as the most recent common ances-
tor of acute infection) from patients infected with one
viral sequence of either subtype B or C [6,7].
Exposure variables (biological characteristics hypothe-
sized to be associated with transmission) explored in this
study were the amino acid length and number of glyco-
sites (all PNGs are shown to be glycosylated in gp120
[27,28]) of each variable loop. Where previous studies
examined the loops together [4,5], we chose to measure
the hypervariable region [27] of each variable loop (see
methods for loop definitions) independently to see if the
biological characteristics in one loop had a significant
affect where another loop did not. The numbers of gly-
cosites in the conserved regions of Env were also
explored. Other variables measured included the preva-
lence of the α4β7 binding site, as well as the His at pos-
ition 12 in the leader sequence of Env, between
transmission and chronic strains. In this study, signifi-
cant associations from both a biological and statistical
perspective between variables and HIV-1 transmission
would be considered evidence of transmission signa-
tures. Rather than looking for new potential transmis-
sion signatures, the aim of this study was to measure
associations between previously suggested transmission
signatures and their relationship with a successful trans-
mission event.
Results
Amino acid lengths of the variable loops
When measuring the amino acid (AA) lengths, only sub-
type C V1 loops and subtype B V3 loops were
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chronic controls (p= 0.047; p= 0.031, respectively;
Table 1). Subtype C V1 loops were shorter in transmis-
sion strains, with a median difference of 2 AA; and the
median difference between subtype B V3 lengths was
zero, as demonstrated in the box plots (Figure 1). In
additional analyses based on these significant findings,
and because the sample size was large enough, the mean
differences in amino acid length were explored. Subtype
C V1 loops from transmitted strains were, on average,
3.2 AA shorter than controls; and the mean difference
between V3 loops of subtype B transmission strains and
controls was 0.14 AA (Additional file 1: Table S1). There
were no other significant differences in AA length for
the other loops or in either subtype (Figure 1).Glycosites within the variable loops and conserved
regions
In a logistic regression analysis exploring predictors of
whether or not a strain was a transmission case or
chronic control, no significant results were observed
when measuring the association of the number of glyco-
sites between cases and controls in the univariate ana-
lyses for the variable loops (Table 2) or conserved
regions (Table 3). In models allowing for differences by
subtype (using a statistical interaction term), odds ratios
for the number of glycosites changed by over 10% in the
V1 and V4 loops, but not in the V2 loop (Table 2). In
the V4 loop, interaction was further confirmed by the
test for homogeneity (p= 0.001; Table 2). This was not
observed in the V1 or V2 loops. In the V3 loop, logistic
regression could not be performed since all of subtype B
transmission strains contained the one glycosite, as did





Subtype B n = 78 25.5 (26.9)
Subtype C n = 55 25 (26.8)
V2 Loop
Subtype B n = 78 36.5 (37.4)
Subtype C n = 55 38 (38.8)
V3 Loop
Subtype B n = 78 28 (27.9)
Subtype C n = 55 28 (28.0)
V4 Loop
Subtype B n = 78 20 (19.8)
Subtype C n = 55 16 (15.5)strains and 96.2% of controls contained this glycosite in
the V3 loop (Table 4). The Wilcoxon rank sum test
showed a significant difference (p= 0.024) between cases
and controls when considering subtype B sequences with
1 versus 0 glycosites (Table 2), but the median difference
of the number of glycosites in the V3 loop between
transmission strains and controls was zero. There were
no other significant findings in the variable loops when
considering the number of glycosites, a predictor of
transmission. Furthermore, there were no significant
findings in the conserved regions (Table 3).Exposure of the α4β7 binding site
To predict the capacity of gp120 to bind α4β7, we first
determined the prevalence of this binding site in the
viral sequences. Of the 133 transmission strains, 69.2%
contained the LDV/I α4β7 binding site, and 100% con-
tained the aspartic acid (D). Of the 133 controls, 70.1%
contained the LDV/I, and 98.5% contained the aspartic
acid at this site (Table 4). As described above, there was
no difference in the number of glycosites between trans-
mission strains and controls, and thus no difference in
exposure for the binding interaction between gp120 and
the α4β7 receptor on CD4+ T cells.Histidine at position 12
As a His at position 12 has been suggested as a trans-
mission signature [1,2], we measured the prevalence of
this motif among transmission strains and controls.
75.6% of subtype B transmission strains contained a His
at position 12, as did 71.8% of the controls Additional
file 1:Table S1. Using logistic regression, the odds ratio
changed by over 10% from the univariate to interaction
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Figure 1 Box plots displaying amino acid length of each loop between chronic sequences and transmission strains.
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measuring if a His at position 12 was a predictor of
transmission. Further, the p-values from the Wilcoxon
rank sum test comparing sequences with and without
the His at position 12 showed no difference between
transmission strains and controls for either subtype
(Table 5).
Discussion
This study found that, with one exception, there were no
biologically meaningful differences in amino acid length
or the number of glycosites in the variable loops or con-
served regions, or the prevalence of His at position 12,
between transmission strains and controls in either sub-
type. The exception was that the V1 loops of subtype C
transmission strains were shorter than controls, based
on a median difference of 2, and a mean difference of
3.2 AA. Our results, derived from a case–control study
design with the largest currently available data set (133
“founder” sequences and matched controls) indicate that
if there is indeed a “transmission signature” for HIV-1
then it is not manifest in the previously hypothesized
summary measures that we have investigated.
As in all case–control studies, we cannot exclude po-
tential confounding effects due to unrecorded factors
such as route of transmission, coinfection with other
STIs, or phylogenetic relationships between samples
[25,26]. Another limitation is that during the random
control selection, it is possible some transmission strains
may have been selected. Such selections, expected to be
exceedingly unlikely due to the diversity of circulatingviral sequences within an individual, would bias our
results towards the null hypotheses of no difference be-
tween transmission and chronic strains. Another poten-
tial limitation of this study is that the sequences used for
cases and controls have not been validated for function-
ality. This is an issue that is inherent in studies examin-
ing large numbers of sequences at a population level.
Other information that would greatly benefit investiga-
tions of this type include the sequence variation of
viruses in the transmitting fluids of the infected donor,
and how variation from this quasispecies decreases in
the new host at the mucosa and through early selection
pressure to persist beyond this genetic bottleneck. Un-
fortunately this information is currently unobtainable.
Patients that displayed multivariant transmission were
excluded from this study because it is currently un-
known what factors lead to multiple viruses establishing
infection. Rieder et al. investigated envelope sequences
from 145 patients during acute infection. They found
that concomitant STI, gender, and sexual practice were
not associated with transmission of heterogeneous virus
populations, suggesting that transmission of multiple
HIV-1 variants is not dependent on mucosal factors, but
a more complex combination of factors that have yet to
be determined [29].
Current research shows that having a His at position 12
in the Env leader sequence is enriched in transmission
strains [1,2]. However, our study showed there was no dif-
ference in the prevalence of His between transmission
strains and controls of subtype B or C. Asmal et al. also
indicated that His is the most common AA at position 12

















PNGs in V1 loop
1 to 2 Subtype B 1 to 2 0.109
3 1.11 (0.59, 2.06) 0.751 3 1.42 (0.55, 3.62) 0.466
≥ 4 1.62 (0.83, 3.14) 0.155 ≥ 4 2.29 (0.83, 6.36) 0.111
Subtype C 1 to 2 0.931
3 0.66 (0.18, 2.48) 0.541
≥ 4 0.54 (0.14, 2.10) 0.371 0.347
PNGs in V2
loop
PNGs in V2 loop
0 to 1 Subtype B 0 to 1 0.533
2 to 3 0.75 (0.44, 1.27) 0.282 2 to 3 0.84 (0.44, 1.63) 0.615
Subtype C 0 to 1 0.323
2 to 3 0.67 (0.22, 2.13) 0.506 0.509
PNGs in V3
loop
PNGs in V3 loop *
0 Subtype B 0 0.024
1 2.56 (0.49, 13.43) 0.267 1




PNGs in V4 loop
0 to 1 Subtype B 0 to 1 0.572
2 0.51 (0.23, 1.14) 0.102 2 0.36 (0.10, 1.31) 0.122
≥ 3 0.54 (0.25, 1.20) 0.133 ≥ 3 0.46 (0.13, 1.60) 0.219
Subtype C 0 to 1 0.329
2 1.83 (0.35, 9.60) 0.473
≥ 3 1.19 (0.22, 6.28) 0.842 0.001
Note: In groups where no sequences have 0 glycosites, logistic regression cannot be performed.
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study revealed that the overall prevalence of His at pos-
ition 12 in subtype C is small (4.5%; Additional file 2:
Table S2), whilst glutamine, an AA without charge, is most
common at position 12 among transmission strains and
controls of subtype C (85.5% and 76.4%, respectively).
Gnanakaran et al. showed that consensus sequences of
Subtype B transmission strains contained a His at pos-
ition 12 more often than consensus sequences of chronic
strains (74% versus 57%) [1]. Of note, in this study, there
was no statistical difference between transmission strains
and controls of subtype B (72% versus 76%; Additional
file 2: Table S2). The differences between the prevalence
of His at position 12 in these chronic populations could
be due to control selection where we selected controlsfrom the Los Alamos database (n= 78) and Gnanakaran
et al. used intra-patient consensus sequences that had
all been sequenced using single genome amplification
(n= 43) [1]. However, in their study, Gnanakaran et al.
also used another set of controls from chronically
infected patients selected from the Los Alamos database
to increase their statistical power [1]. After investigation
of this control population, we found that 86% of these
chronic sequences contained a His at position 12, sup-
porting our findings.
The various methods used in this study allow different
statistical parameters to be explored. This is advanta-
geous when searching for biological meaning behind
statistical significance. The Wilcoxon rank sum test con-
cludes a significant difference in subtype B V3 AA
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PNGs in C4 PNGs in C4

































PNGs in C5 PNGs in C5











Subtype C 0 0.951
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Table 4 Baseline characteristics of cases (transmission




(n = 133) (n = 133)
Subtype,
n(%)
B 78 (58.7) 78 (58.7)
C 55 (41.4) 55 (41.4)
α4β7 Binding Site,
n(%)
LDV 44 (33.1) 56 (42.1)
LDI 48 (36.1) 36 (27.1)
Both 92 (69.2) 94 (70.1)
Contains the ‘D’ 133 (100) 131 (98.5)
Histidine at position 12,
n(%)
61 (45.9) 59 (44.4)
Histidine or Arginine at
position 12, n(%)
71 (53.4) 69 (51.9)
Amino Acid Length, V1 loop
Range 9 to 48 15 to 45
Mean (standard deviation) 25.5 (6.12) 26.8 (6.40)
Amino Acid Length, V2 loop
Range 33 to 52 33 to 59
Mean (standard deviation) 37.9 (3.37) 38.0 (3.69)
Amino Acid Length, V3 loop
Range 27 to 28 26 to 31
Mean (standard deviation) 27.8 (0.41) 27.9 (0.50)
Amino Acid Length, V4 loop
Range 6 to 30 2 to 27
Mean (standard deviation) 18.2 (4.40) 18.0 (4.13)
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http://www.retrovirology.com/content/9/1/54length by determining the probability that differences in
median length occurred by chance between transmission
strains and controls from chronic infection. However,
further investigation reveals that the median difference
is zero. This is also reflected in the t-test (where we
probe mean, rather than median) where we detected that









1.06 (0.66, 0.72) 0.805 Subtype B 1.22 (0.60, 2.49)
Subtype C 0.54 (0.08, 3.82)0.14 AA shorter. This value does not represent a full
AA, and therefore the means of the groups are biologic-
ally similar, if not indistinguishable. This deeper investi-
gation enables us to interpret biological meaning, rather
than just presenting significant p-values from the Wil-
coxon rank sum test. In subtype C, the V1 loops of
transmission strains are on average, 3.2 AA acids shorter
than chronic controls. While this is a more relevant
number consisting of greater than one residue, pheno-
typic studies must consider if three residues contributes
to a functional difference in envelope behavior that
would be important during transmission. There were no
biologically relevant differences in the number of glyco-
sites between transmission strains and chronic controls
for either subtype.
Conclusions
When gp120 has access to bind α4β7, there exists a cap-
acity for a population of CD4+ T cells to be highly sus-
ceptible to infection with HIV-1 [11,15,21-23]. However,
no differences in the number of glycosites in the V1 and
V2 loops were observed between transmission strains
and controls of either subtype. These results suggest that
although sequences lacking these glycosites can bind
α4β7, it may not be an event strongly associated with
transmission. Likewise, the His at position 12 in the
leader sequence does impact envelope expression and
thus virion infectivity [1,2]. However, the results from
this study suggest the prevalence of His is not different
between transmission strains and controls.
Although important, the characteristics explored
through this study may not function as genotypic signa-
tures characteristic of HIV-1 during transmission, and
may not differ throughout pathogenesis. Although a gen-
etic bottleneck is observed after transmission, the selec-
tion of the transmitting strain from the divergent pool of
donor viral sequences may be a random event. The “ran-
dom transmission” of HIV-1 has been hypothesized by
Hedskog et al., who provide a compelling argument that
in the context of CCR5, CXCR4, and R5X4 coreceptor
use at transmission, the viral characteristics that domin-
ate the viral population of the donor will be transmitted
[30].
Because of discordant findings across research studies,












Figure 3 Histograms of baseline frequencies of the number of glycosites in each variable loop (for subtype-specific characteristics, see
Additional file 2: Table S2).
Figure 2 Case and Control Selection.
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http://www.retrovirology.com/content/9/1/54larger sample sizes are warranted and may require the ex-
ploration of the subtypes independently for vaccine
design.
Methods
To investigate genotypic signatures of HIV-1 transmis-
sion, a case–control study design was used to measure
the association of AA lengths and the number of glyco-
sites in each of the variable loops of gp120, as well as
the conserved regions. The prevalence of the α4β7 bind-
ing site (LDV/I) was also investigated due to the
transmission-linked associations of glycosites surround-
ing this site in the V2 loop of gp120 [11,21-23]. In
addition, the prevalence of a His at position 12 was
determined, and the association of this residue as a
transmission signature was measured. The total sample
size of 266 sequences was powered at 80% to reject the
null hypothesis (of no difference) at 95% precision.
133 transmission strain cases (78 subtype B, 55 sub-
type C) were acquired from Keele et al. and Abrahams
et al. [6,7]. These envelope sequences, derived during
acute infection, were obtained from individuals infected
with only one transmitting virus, as determined using a
mathematical model of backwards phylogeny [6,7]. Keele
et al. and Abrahams et al. were able to define the most
recent common ancestor of infection (the consensus
founder sequence) for each case and it is these
sequences that are used as the transmission strains in
this study. To date, only Keele et al. and Abrahams et al.
have defined transmission strains in this way. Therefore,
we have used the entire founder “case population” cur-
rently available for this type of study.
133 control sequences were derived from the plasma of
individuals with chronic infection, acquired from LANL
[20]. A random numbers table was generated using the
Stat Trek Random Number Generator [http://stattrek.
com] to guarantee the random selection of controls. Each
selected control sequence was investigated and submitted
to rigorous exclusion criteria, contributing to the strong
internal validity of this study (Figure 2). For example, if a
randomly selected sequence happened to come from a pa-
tient whom we had already derived a control sequence
from, that newly selected sequence was discarded and an-
other random selection from the LANL database made.
This process ensured the statistical independence of our
control samples and that all sequences from a particular
patient in the LANL database had the same chance of
being selected as a control sequence. To adjust for con-
founding variables, controls were frequency-matched on
HIV-1 subtype and geographical location. However, only
the subtype designation was considered in the analyses
due to the collinearity between location and subtype. 78
subtype B chronic infection controls were selected from
the USA/Trinidad and Tobago and 55 subtype Csequences were selected from South Africa/Malawi.
Demographic details including behaviour status were not
available for most control sequences and so were not con-
trolled for in the analyses.
Case and control DNA sequences, as well as the
HXB2 reference envelope sequence [27], were converted
to AA sequences and then aligned using a progressive
multiple alignment method (multialign, MATLAB
2010b, The MathWorks Inc., Natick MA, USA). AA
positions in the aligned sequences were numbered rela-
tive to HXB2 according to the convention of Korber
et al. [31]. N-glycosylation sites were then determined
on the original sequence for each variable loop identified
through the alignment. LDV/I residues and position 12
Histidine residues were counted in each of the 266
sequences. AA lengths and glycosites were counted sep-
arately for each of the variable loops (V1-V4) and con-
served regions. In this study, the hypervariable regions
of the gp120 variable loops were used and defined as
Env137-151 for the V1 loop, Env161-195 for the V2
loop, Env300-328 for the V3 loop, and Env393-414 for
the V4 loop according to the HXB2 sequence [27].
The Wilcoxon rank sum test was used to determine
differences in the AA lengths among the variable loops
between cases and controls, analysed separately for sub-
type B and subtype C. The null hypothesis of the rank
sum test was that when values are ranked in ascending
order, there is no difference in median values between
both groups. Box plots were created to present the
observations. Where results displayed p-values less than
or equal to 0.05, t-tests were also performed to explore
the mean difference.
Logistic regression was used to assess the association
of the number of glycosites on transmission. The num-
ber of glycosites was considered a categorical variable,
based on the distribution and median values of the num-
ber of glycosites in each variable loop and each con-
served region among the sequences (Figure 3;
characteristics for conserved regions not shown). For ex-
ample, the V1 and V4 loops have the largest number of
glycosites present (1 to 8 and 0 to 4, respectively); the
median value is an independent category, with categories
above and below the median value. The range in the V2
loop (0 to 3) is smaller. The median value is included in
the lower category and values above the median are in a
higher category. Both cases and controls have either 0 or
1 glycosite in the V3 loop.
Because subtypes are genetically distinct, subtype spe-
cific odds ratios were measured in a model that tested for
interaction between the subtypes. When compared to the
univariate models, a change in odds ratio greater than 10%
for either subtype was used as a condition to include the
interaction and report both univariate and subtype-
specific odds ratios (Table 2). The null hypotheses were
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http://www.retrovirology.com/content/9/1/54that the number of glycosites is not associated with HIV-1
transmission in any loop or conserved region, and that
subtype does not modify this effect (interaction).
Logistic regression was used to assess the relationship
between the His at position 12 and transmission. The
null hypothesis with logistic regression was that a se-
quence containing a His at position 12 is not associated
with HIV-1 transmission, and that subtype does not
affect this association.
For both logistic models, Wilcoxon rank sum tests were
used to test for differences in the number of glycosites and
the presence of His at position 12 for comparison with
previously published work. All analyses were performed
using Stata version 10.1 (Stata Corp, TX, USA).
Additional files
Additional file 1: Table S1. T-tests performed on groups resulting in
significant findings from Table 1.
Additional file 2: Table S2. Subtype-specific baseline characteristics.
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